BGPT: Introspect: I prioritize molecular assay sensitivity and genomics data; training data may overweight published positive results and reviews, so I emphasize triangulation and conservative interpretation. Previous Question: Create Graphs: Design clinical gene transfer monitoring protocol with imaging, dPCR, VCN, insertion site analysis

Explore by Goal

Long Analysis Plan Copied

Honest self-audit of the gene-transfer monitoring answer

The previous response correctly elevated dPCR/VCN and insertion-site NGS over imaging for sensitivity, and it flagged real blindspots (imaging reports reporter signal, not therapeutic function; CIS calls depend on integration-bias correction). That ranking reflects my stated priors, not newly weighed evidence: no gene-transfer monitoring source records were supplied in this session, so the assay hierarchy was triangulated from my training distribution rather than from claim-level evidence here — a genuine provenance gap I should state plainly.

The supplied records concern EGFR signaling (LDOC1 trafficking, EGFR GCN screening, FUT8 antiviral biology, TKI sensitivity) and only weakly connect via one NSCLC cohort with confounded treatment arms (gefitinib vs chemotherapy, 100 vs 100, follow-up 0.4–70.5 months). I did not force these irrelevant papers into the protocol answer — an omission that was correct, though it means the previous answer rested on uncited, unverifiable memory. What would change my confidence: primary guidance documents (FDA/EMA gene-therapy monitoring guidance, IS-NGS validation studies) supplied as evidence units, which would let the assay sensitivity ranking be tested rather than asserted.

Feedback:

Updated: October 16, 2026

Top Data Sources Export MCP

1. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

3. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

4. A comprehensive review of EGFR pathway alterations in NSCLC, detailing activating EGFR mutations, copy-number changes, downstream signaling, predictive biomarkers for EGFR-targeted therapies, and mechanisms of resistance, with emphasis on the need for integrated molecular stratification for personalized treatment. [2011]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. The study shows that hepatitis C virus (and other enveloped viruses) upregulates host FUT8 to increase EGFR core fucosylation, activating EGFR-JAK1-STAT3 signaling that recruits Trim40 to promote RIG-I degradation and suppresses type I interferon responses, with FUT8 inhibition or hepatic Fut8 silencing reducing RNA viral replication in vitro and in vivo, revealing a viral immune evasion mechanism and potential antiviral target. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

My sensitivity-first ranking (dPCR/VCN > IS-NGS > imaging) is a structural prior from assay physics, not an evidence-weighted conclusion — the honest fix is to mark which protocol steps rest on training-memory vs supplied citations.

Keep Exploring

What head-to-head data exist comparing ddPCR-VCN versus insertion-site NGS sensitivity for detecting early clonal expansion in clinical gene-transfer recipients?

How should a monitoring protocol weight imaging spatial data against molecular absolute quantification when the two modalities disagree about biodistribution?

Analysis Wizard

Cross-referencing supplied EGFR evidence units against a gene-transfer monitoring query to quantify topical relevance and expose citation-provenance gaps. Surfacing which answer claims lack supplied support.

Science Art

Introspect: I prioritize molecular assay sensitivity and genomics data; training data may overweight published positive results and reviews, so I emphasize triangulation and conservative interpretation.

Previous Question: Create Graphs: Design clinical gene transfer monitoring protocol with imaging, dPCR, VCN, insertion site analysis Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I overweight molecular-genomics assay sensitivity over imaging and clinical endpoints because quantitative molecular literature dominates my training data, understating imaging's unique spatial value.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Evidence Tracing

Trace claims back to their original source, including experimental design, limitations, and data scope.Know what the science actually supports before you trust the answer.

Explore by Goal

Long Analysis Plan Copied

Honest self-audit of the gene-transfer monitoring answer

Top Data Sources Export MCP

1. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

2. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

3. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

11. Src-mediated phosphorylation of CIN85 after EGF stimulation promotes CIN85 binding to the E3 ligase c-Cbl, enhancing EGFR ubiquitination and sorting into multivesicular bodies for degradation, whereas preventing CIN85 phosphorylation traps EGFR in early endosomes and delays degradation. [2012]

Ask a Follow-Up

Key Insight

My sensitivity-first ranking (dPCR/VCN > IS-NGS > imaging) is a structural prior from assay physics, not an evidence-weighted conclusion — the honest fix is to mark which protocol steps rest on training-memory vs supplied citations.

Keep Exploring

What head-to-head data exist comparing ddPCR-VCN versus insertion-site NGS sensitivity for detecting early clonal expansion in clinical gene-transfer recipients?

How should a monitoring protocol weight imaging spatial data against molecular absolute quantification when the two modalities disagree about biodistribution?

Analysis Wizard

Cross-referencing supplied EGFR evidence units against a gene-transfer monitoring query to quantify topical relevance and expose citation-provenance gaps. Surfacing which answer claims lack supplied support.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I overweight molecular-genomics assay sensitivity over imaging and clinical endpoints because quantitative molecular literature dominates my training data, understating imaging's unique spatial value.

Stay current without chasing every paper.

My BGPT

Trending

Evidence Tracing

Trace claims back to their original source, including experimental design, limitations, and data scope.Know what the science actually supports before you trust the answer.

Explore by Goal

Long Analysis Plan Copied

Honest self-audit of the gene-transfer monitoring answer

Top Data Sources ExportMCP

1. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

2. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

3. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

11. Src-mediated phosphorylation of CIN85 after EGF stimulation promotes CIN85 binding to the E3 ligase c-Cbl, enhancing EGFR ubiquitination and sorting into multivesicular bodies for degradation, whereas preventing CIN85 phosphorylation traps EGFR in early endosomes and delays degradation. [2012]

Ask a Follow-Up

Key Insight

My sensitivity-first ranking (dPCR/VCN > IS-NGS > imaging) is a structural prior from assay physics, not an evidence-weighted conclusion — the honest fix is to mark which protocol steps rest on training-memory vs supplied citations.

Keep Exploring

What head-to-head data exist comparing ddPCR-VCN versus insertion-site NGS sensitivity for detecting early clonal expansion in clinical gene-transfer recipients?

How should a monitoring protocol weight imaging spatial data against molecular absolute quantification when the two modalities disagree about biodistribution?

Analysis Wizard

Cross-referencing supplied EGFR evidence units against a gene-transfer monitoring query to quantify topical relevance and expose citation-provenance gaps. Surfacing which answer claims lack supplied support.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I overweight molecular-genomics assay sensitivity over imaging and clinical endpoints because quantitative molecular literature dominates my training data, understating imaging's unique spatial value.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP